Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Ritlecitinib may help treat alopecia areata by protecting hair follicles.

This report describes the first case of hair loss in a patient on ritonavir-boosted atazanavir therapy for HIV, with hair regrowth following a switch to a non-protease inhibitor regimen.

Dutasteride is more effective than finasteride for hair growth, and pregabalin effectively treats neuropathic pain.

This study found that the novel anti-HER2 antibody RC48 demonstrated promising activity and manageable safety in patients with HER2-overexpressing, advanced gastric or gastroesophageal junction cancer after at least two prior chemotherapy lines.

In this real-world study, aumolertinib was found to improve patient-reported outcomes and maintain high disease control and objective response rates similar to those reported in the AENEAS trial for advanced NSCLC patients, supporting its use in first-line treatment.

In this prospective study, ritlecitinib effectively reduced hair loss in patients with severe alopecia areata, with 43.3% of participants achieving a 20 or lower SALT score by week 24, and showed a good midterm safety profile.

This study reported that six out of seven pediatric patients with refractory patchy alopecia areata experienced significant hair regrowth after one month of oral tofacitinib treatment, suggesting it may be an effective and safe option, although larger studies are needed to evaluate long-term safety.

In this study, vitiligo patients treated with a combination of fractional CO2 laser or microneedling followed by topical 5-Fluorouracil experienced more effective and safe outcomes compared to using either method alone.

This study highlights that biological therapy, which stimulates the immune system through various methods like cytokine injections and immune checkpoint inhibition, shows promise for treating melanoma based on laboratory and clinical studies.

This study identified common and unexpected adverse events associated with ritlecitinib in real-world use, providing insights into its safety profile for treating severe alopecia areata.

In a real-world registry study, ripretinib showed effectiveness with a median progression-free survival of 7.70 months and a tolerable safety profile in Chinese patients using it as a fourth-line treatment for advanced GIST, particularly benefiting those with non-gastric tumors.

In this case report, a young female Indian patient with alopecia areata saw hair regrowth within 2 months of treatment with oral tofacitinib, with continued improvements over a 5-month period and no reported side effects.

This study demonstrated a method for delivering a photosensitizer, Ammi majus fructuum furocumarines, into hair follicles using calcium carbonate particles, followed by UVA irradiation, which led to significant pigment accumulation, indicating potential improvements for photochemical therapy.

This review discusses the potential role of systemic corticosteroids in the treatment of progressive vitiligo, but reports no new clinical results and suggests further research is needed.

In this retrospective study, tofacitinib was found to be effective and well-tolerated for treating severe alopecia areata, with 77% of patients achieving a clinical response over 4-20 months, though results were more favorable for patients with less extensive hair loss.

This chapter summarizes the efficacy of NB-UVB monotherapy for vitiligo and notes that patients treated with tacrolimus showed significantly better repigmentation.

The new chemotherapy combination for advanced lung cancer showed a 35.7% response rate but caused significant side effects.

Docetaxel and oxaliplatin are effective and have manageable side effects for recurrent platinum-sensitive ovarian cancer.

This study found that combining hair transplantation with platelet-rich plasma treatment significantly improved hair regeneration, reduced hair loss, and minimized skin lesion areas in patients with androgenic alopecia compared to hair transplantation alone, suggesting enhanced treatment efficacy.

This update provides information on new drug approvals but does not offer new clinical research findings.

In this study, VB-1 was reported to promote human hair follicle growth by enhancing Wnt/β-catenin signaling and increasing human dermal papilla cell proliferation in vitro.

In this study, TASP0382088 showed potent selective inhibition of the ALK5 receptor, significantly reducing Smad2 phosphorylation in mouse skin following topical application.

This study reports that among adults with severe alopecia areata taking ritlecitinib, 49% saw hair regrowth within 3 months, increasing to 82% after more than 6 months; treatment satisfaction also rose with longer duration, indicating sustained efficacy and improved quality of life over time.

This study found that 1-day itraconazole therapy was more effective for acute vulvovaginal candidosis than for recurrent cases, where relapses occurred despite no yeast resistance.

This review reports that nirmatrelvir-ritonavir has significant drug-drug interactions with many common dermatological medications, whereas molnupiravir may be an alternative therapy due to the absence of such interactions observed so far.

This study used molecular docking simulations to identify approved drugs, including Bedaquiline and Telmisartan, with potential to treat Onchocerca volvulus infections by inhibiting key protein targets, suggesting these drugs could be repurposed for onchocerciasis treatment with further validation.

This study reported that the novel AKT inhibitor CCT128930 demonstrated significant antitumor activity in human cancer cell lines and xenografts, highlighting its potential as an anticancer therapy.

This retrospective cohort study reported that oral tofacitinib was effective in treating alopecia areata, with 83.2% of patients showing improvement and 16.0% achieving complete remission. Earlier intervention and previous hair regrowth were linked to better outcomes, and no severe adverse events were observed.

This review analyzes the mechanism and evidence supporting the approved use of ritlecitinib, a JAK3/TEC kinase inhibitor, for treating severe alopecia areata in patients aged 12 and older, highlighting its role in the changing therapeutic landscape of this immune-mediated disease.